Dosing of Direct Oral Anticoagulants in Patients with Moderate Chronic Kidney Disease in US Clinical Practice: Results from the Outcomes Registry for Better Informed Treatment of AF (ORBIT-AF II)
暂无分享,去创建一个
D. Singer | G. Fonarow | L. Allen | B. Gersh | P. Kowey | J. Piccini | K. Mahaffey | E. Peterson | B. Steinberg | J. Reiffel | G. Naccarelli | L. Thomas | J. Freeman | L. Jackson | Rosalia G Blanco | P. Schrader | Rosalia G. Blanco
[1] Aubrey E. Jones,et al. Real-world study of direct oral anticoagulant dosing patterns in patients with atrial fibrillation , 2019, Pharmacy practice.
[2] R. Arbel,et al. Effectiveness and Safety of Off-Label Dose-Reduced Direct Oral Anticoagulants in Atrial Fibrillation. , 2019, The American journal of medicine.
[3] Y. Okumura,et al. Clinical Outcomes of Off-Label Dosing of Direct Oral Anticoagulant Therapy Among Japanese Patients With Atrial Fibrillation Identified From the SAKURA AF Registry. , 2019, Circulation journal : official journal of the Japanese Circulation Society.
[4] Gregory Y H Lip,et al. Non-vitamin K antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunction. , 2017, Annals of translational medicine.
[5] Xiaoxi Yao,et al. Non-Vitamin K Antagonist Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Renal Dysfunction. , 2017, Journal of the American College of Cardiology.
[6] D. Singer,et al. Off-Label Dosing of Non-Vitamin K Antagonist Oral Anticoagulants and Adverse Outcomes: The ORBIT-AF II Registry. , 2016, Journal of the American College of Cardiology.
[7] A. Camm,et al. XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation , 2015, European heart journal.
[8] M. Lamberts,et al. Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study. , 2014, Journal of the American College of Cardiology.
[9] G. Fonarow,et al. Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II: rationale and design of the ORBIT-AF II registry. , 2014, American heart journal.